Nilotinib Viatris

Leaflet accompanying the packaging: information for the user

Nilotinib Viatris, 50 mg, hard capsules

Nilotinib Viatris, 150 mg, hard capsules

Nilotinib Viatris, 200 mg, hard capsules

Nilotinib

You should carefully read the contents of the leaflet before taking the medicine, as it contains important information for the patient.

• You should keep this leaflet, so that you can read it again if you need to.
• In case of any doubts, you should consult a doctor or pharmacist.
• This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm them, even if their symptoms are the same as yours.
• If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. See section 4.

Table of contents of the leaflet

• 1. What is Nilotinib Viatris and what is it used for
• 2. Important information before taking Nilotinib Viatris
• 3. How to take Nilotinib Viatris
• 4. Possible side effects
• 5. How to store Nilotinib Viatris
• 6. Contents of the pack and other information

1. What is Nilotinib Viatris and what is it used for

What is Nilotinib Viatris

Nilotinib Viatris is a medicine that contains the active substance nilotinib.

What is Nilotinib Viatris used for

Nilotinib Viatris is used to treat a type of leukemia called chronic myeloid leukemia (CML) with Philadelphia chromosome positive (Ph+). CML is a blood cancer that causes the body to produce too many abnormal white blood cells. Nilotinib Viatris is used to treat adult patients and children and adolescents with newly diagnosed CML or patients with CML who have not responded to previous treatment, including imatinib, or have experienced severe side effects that prevent them from continuing previous treatment.

How Nilotinib Viatris works

In patients with CML, a change in DNA (genetic material) leads to the production of a signal that causes the body to produce abnormal white blood cells. Nilotinib Viatris blocks this signal and thereby prevents the production of these abnormal cells.

Monitoring treatment with Nilotinib Viatris

During treatment, regular tests will be performed, including blood tests. These tests determine:

• the number of blood cells (white blood cells, red blood cells, and platelets) in the body to assess how Nilotinib Viatris is tolerated.
• the function of the pancreas and liver in the body to assess how Nilotinib Viatris is tolerated.
• the concentration of electrolytes in the body (potassium, magnesium), which are important for heart function.
• the concentration of sugar and fats in the blood. Heart rate will also be monitored using a device that measures the electrical activity of the heart (a test called EKG).

The doctor will regularly evaluate the treatment results and decide whether the patient should continue taking Nilotinib Viatris. If the patient finds out that they need to stop treatment with this medicine, the doctor will continue to monitor the CML condition and may recommend that the patient resume treatment with Nilotinib Viatris if their condition requires it. If there are any questions about the action of Nilotinib Viatris or the reason it was prescribed, the patient should consult their doctor.

2. Important information before taking Nilotinib Viatris

The patient should strictly follow the doctor's instructions. They may differ from the general information contained in this leaflet.

When not to take Nilotinib Viatris

• if the patient is allergic to nilotinib or any of the other ingredients of this medicine (listed in section 6). If the patient suspects that they may be allergic, they should tell their doctor before starting treatment with Nilotinib Viatris.

Warnings and precautions

Before starting treatment with Nilotinib Viatris, the patient should discuss the following with their doctor or pharmacist:

• if the patient has previously experienced cardiovascular events such as heart attack, chest pain (angina), stroke, or poor circulation to the legs (claudication) or if the patient has risk factors for cardiovascular disease, such as high blood pressure (hypertension), diabetes, or lipid disorders;
• if the patient has heart problems, such as abnormal electrical activity called "QT interval prolongation";
• if the patient is taking medicines that lower cholesterol levels in the blood (statins) or affect heart function (anti-arrhythmic drugs) or liver function (see "Other medicines and Nilotinib Viatris");
• if the patient has low levels of potassium or magnesium;
• if the patient has liver or pancreas problems;
• if the patient experiences symptoms such as easy bruising, fatigue, or shortness of breath or if they experience recurring infections;
• if the patient has had surgery to remove the entire stomach (total gastrectomy);
• if the patient has had or may currently have hepatitis B virus infection; this is because Nilotinib Viatris may cause the hepatitis B virus to become active again, which can be life-threatening in some cases; patients will be closely monitored by their doctor for signs of this infection before starting treatment.

During treatment with Nilotinib Viatris

• if the patient experiences loss of consciousness (fainting) or irregular heartbeat, they should immediately tell their doctor, as this may be a sign of a serious heart condition. QT interval prolongation or irregular heartbeat can lead to sudden death. Sudden death has been reported in patients taking nilotinib.
• if the patient experiences: rapid heartbeat, severe weakness or paralysis, seizures, or sudden changes in thinking or concentration, they should immediately tell their doctor, as these may be symptoms of a condition called tumor lysis syndrome; tumor lysis syndrome has been rarely reported in patients treated with nilotinib.
• if the patient experiences chest pain or discomfort, numbness or weakness, difficulty walking or speaking, pain, discoloration, or feeling of cold in a limb, they should immediately tell their doctor, as these may be signs of cardiovascular events. Serious cardiovascular events, including peripheral arterial disease, ischemic heart disease, and stroke, have been reported in patients taking nilotinib.

The doctor should check the patient's lipid and sugar levels in the blood before starting treatment with Nilotinib Viatris and during treatment.

• if the patient experiences swelling of the feet or hands, generalized edema, or rapid weight gain, they should tell their doctor, as these may be signs of fluid retention. Fluid retention has been reported in patients treated with nilotinib. Parents of children treated with Nilotinib Viatris should inform their doctor if any of the above situations apply to their child.

Children and adolescents

Nilotinib Viatris is used to treat children and adolescents with CML. There is limited experience with the use of this medicine in children under 2 years of age. There is limited experience with the use of Nilotinib Viatris in children under 10 years of age with newly diagnosed disease and in patients under 6 years of age who have not responded to previous CML treatment. Some children and adolescents taking Nilotinib Viatris may grow more slowly than normal. The doctor will monitor growth during regular visits.

Nilotinib Viatris and other medicines

Nilotinib Viatris may affect the action of other medicines. The patient should tell their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take. This is especially important for medicines such as:

• anti-arrhythmic drugs - used to treat irregular heart rhythm;
• chloroquine, halofantrine, clarithromycin, haloperidol, methadone, moxifloxacin - these are medicines that may have a negative effect on the electrical activity of the heart;
• ketokonazole, itraconazole, voriconazole, clarithromycin, telithromycin - used to treat infections;
• ritonavir - a protease inhibitor used to treat HIV infection;
• carbamazepine, phenobarbital, and phenytoin - used to treat epilepsy;
• rifampicin - used to treat tuberculosis;
• St. John's Wort (also known as Hypericum perforatum) - a herbal product used to treat depression and other conditions;
• midazolam - used as a sedative before surgery;
• alfentanil and fentanyl - used to treat pain and as sedatives before and during surgery or medical procedures;
• cyclosporine, sirolimus, and tacrolimus - medicines used to suppress the body's immune system and fight infections, often used to prevent organ rejection in patients who have received a liver, heart, or kidney transplant;
• dihydroergotamine and ergotamine - used to treat dementia;
• lovastatin and simvastatin - used to treat high levels of fats in the blood;
• warfarin - used to treat blood clotting disorders (such as thrombosis);
• astemizole, terfenadine, cisapride, pimozide, quinidine, bepridil, or ergot alkaloids (ergotamine, dihydroergotamine).

The patient should avoid taking the above medicines while taking Nilotinib Viatris. If the patient is taking any of these medicines, their doctor may prescribe alternative medicines. If the patient is taking a statin (a type of medicine that lowers cholesterol levels in the blood), they should talk to their doctor or pharmacist. Nilotinib Viatris taken with certain statins may increase the risk of muscle problems caused by statins, which can rarely lead to serious muscle damage (rhabdomyolysis) that can cause kidney damage. Additionally, before taking Nilotinib Viatris, the patient should tell their doctor or pharmacist if they are taking any medicines that neutralize stomach acid, such as antacids. The following medicines should be taken separately from Nilotinib Viatris:

• H2 receptor blockers, which reduce stomach acid production. H2 receptor blockers should be taken about 10 hours before and about 2 hours after taking Nilotinib Viatris.
• Antacids containing aluminum hydroxide, magnesium hydroxide, and simethicone, which neutralize stomach acid. These medicines should be taken about 2 hours before or about 2 hours after taking Nilotinib Viatris.

The patient should also tell their doctor if they are already taking Nilotinib Viatris and have been prescribed a new medicine that has not been taken before with Nilotinib Viatris.

Taking Nilotinib Viatris with food and drink

Nilotinib Viatris should not be taken with food.Food can increase the absorption of Nilotinib Viatris and increase the concentration of Nilotinib Viatris in the blood, even to a harmful level. The patient should not drink grapefruit juice or eat grapefruit. These may increase the concentration of Nilotinib Viatris in the blood, even to a harmful level.

Pregnancy and breastfeeding

• Nilotinib Viatris should not be taken during pregnancyunless it is absolutely necessary. If the patient is pregnant or thinks they may be pregnant, they should inform their doctor, who will discuss the possibility of taking this medicine with them.
• Women who may become pregnantshould be advised by their doctor to use highly effective contraception during treatment and for up to two weeks after treatment ends.
• Nilotinib Viatris should not be taken during breastfeedingand for two weeks after the last dose. If the patient is breastfeeding, they should inform their doctor. If the patient is pregnant, breastfeeding, or thinks they may be pregnant, or is planning to have a child, they should consult their doctor or pharmacist before taking this medicine.

Driving and using machines

If the patient experiences side effects after taking this medicine, such as dizziness or vision disturbances, which may affect their ability to drive or operate machinery, they should stop driving or operating machinery until these side effects have resolved.

Nilotinib Viatris contains lactose

This medicine contains lactose (also known as milk sugar). If the patient has been diagnosed with intolerance to some sugars, they should contact their doctor before taking this medicine.

Nilotinib Viatris 50 mg and 150 mg contain sodium

The medicine contains less than 1 mmol (23 mg) of sodium per dose, which means it is considered "sodium-free".

3. How to take Nilotinib Viatris

This medicine should always be taken exactly as prescribed by the doctor or pharmacist. If the patient is unsure, they should consult their doctor or pharmacist.

What dose of Nilotinib Viatris to take

Adult patients

• Patients with newly diagnosed CML: The recommended dose is 600 mg per day. This dose is achieved by taking two 150 mg hard capsules twice a day.
• Patients who have not responded to previous CML treatment: The recommended dose is 800 mg per day. This dose is achieved by taking two 200 mg hard capsules twice a day.

Children and adolescents

• The dose given to the child depends on the child's weight and height. The doctor will calculate the correct dose to be taken and tell the patient which capsules and how many capsules of Nilotinib Viatris to give to the child. The total daily dose given to the child should not exceed 800 mg.

The doctor may prescribe a lower dose depending on how the patient responds to treatment.

Elderly patients (65 years and older)

Nilotinib Viatris can be given to patients 65 years and older at the same doses as other adults.

When to take Nilotinib Viatris

Hard capsules should be taken:

• twice a day (about every 12 hours);
• at least 2 hours after eating any food;
• the patient should wait 1 hour after taking the medicine before eating. If the patient is unsure about the timing of taking this medicine, they should consult their doctor or pharmacist. Nilotinib Viatris should be taken at the same time every day to help remember to take the capsules.

How to take Nilotinib Viatris

• Hard capsules should be swallowed whole with water.
• Hard capsules should not be taken with food.
• Hard capsules should not be opened. For patients with difficulty swallowing, including children and adolescents who are unable to swallow hard capsules, other nilotinib products should be used instead of Nilotinib Viatris.

How long to take Nilotinib Viatris

Nilotinib Viatris should be taken every day for as long as the doctor prescribes. Treatment is long-term. The doctor will regularly monitor the patient's condition to assess whether treatment is having the desired effect. The doctor may consider stopping treatment with Nilotinib Viatris based on specific criteria. If the patient has any further doubts about the duration of treatment with Nilotinib Viatris, they should consult their doctor or pharmacist.

Taking more than the recommended dose of Nilotinib Viatris

If the patient takes more than the recommended dose of Nilotinib Viatris or takes it by mistake, they should immediately consult their doctor or go to the hospital. The packaging of the hard capsules and the leaflet should be shown to the doctor or hospital staff. Medical attention may be necessary.

Missing a dose of Nilotinib Viatris

If the patient misses a dose, they should take the next dose according to the established schedule. The patient should not take a double dose to make up for the missed capsules.

Stopping treatment with Nilotinib Viatris

This medicine should be taken for as long as the doctor prescribes. Stopping treatment with Nilotinib Viatris without consulting a doctor may put the patient at risk of their condition getting worse, which can be life-threatening. If the patient is considering stopping treatment with Nilotinib Viatris, they should discuss this with their doctor, nurse, and/or pharmacist.

Doctor's recommendation to stop treatment with Nilotinib Viatris

The doctor will regularly evaluate the treatment results using specific diagnostic tests and decide whether the patient should continue taking this medicine. If the patient is told to stop treatment with Nilotinib Viatris, the doctor will continue to closely monitor the patient's CML condition before, during, and after stopping treatment with Nilotinib Viatris and may recommend that the patient resume treatment with Nilotinib Viatris if necessary due to their condition. If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.

4. Possible side effects

Like all medicines, Nilotinib Viatris can cause side effects, although not everybody gets them. Most side effects are mild to moderate and go away after a few days or weeks of treatment.

Some side effects can be serious.

• musculoskeletal pain: joint and muscle pain
• cardiac disorders: chest pain or discomfort, high or low blood pressure, irregular heartbeat (fast or slow), palpitations, fainting, blue discoloration of the lips, tongue, or skin
• arterial occlusion: pain, discomfort, weakness, or cramping of the muscles in the legs, which may be caused by reduced blood flow, ulcers on the legs or hands that heal slowly or not at all, and noticeable changes in skin color (blue or pale) or temperature (cooling) of the legs or hands, toes, or fingers in the affected limbs
• hypothyroidism: weight gain, fatigue, hair loss, muscle weakness, feeling cold
• hyperthyroidism: rapid heartbeat, bulging eyes, weight loss, swelling of the front of the neck
• renal or urinary disorders: feeling thirsty, dry skin, irritability, dark urine, reduced urine output, difficult or painful urination, frequent urination, blood in the urine, abnormal urine color
• high blood sugar: excessive thirst, excessive urine output, increased appetite with weight loss, feeling tired
• dizziness: dizziness or feeling of spinning
• pancreatitis: severe abdominal pain (in the middle or left side)
• skin disorders: painful, red lumps, skin pain, redness, scaling, or blistering of the skin
• fluid retention: rapid weight gain, swelling of the hands, ankles, feet, or face
• migraine: severe headache, often accompanied by nausea, vomiting, and sensitivity to light
• blood disorders: fever, easy bruising or bleeding for no apparent reason, severe or frequent infections, weakness for no apparent reason
• thrombosis: swelling and pain in one part of the body
• neurological disorders: weakness or paralysis of limbs or face, difficulty speaking, severe headaches, seeing, feeling, or hearing things that do not exist, changes in vision, loss of consciousness, confusion, disorientation, tremors, feeling of tingling, pain, or numbness
• respiratory disorders: difficulty breathing or pain while breathing, cough, wheezing breath with or without fever, swelling of the feet or legs
• gastrointestinal disorders: abdominal pain, nausea, vomiting blood, black or bloody stools, constipation, heartburn, acid reflux, abdominal swelling

Some side effects are very common(may affect more than 1 in 10 people)

• diarrhea
• headache
• fatigue
• muscle pain
• itching, rash
• nausea
• constipation
• vomiting
• hair loss
• limb pain, bone pain, and back pain after stopping treatment with Nilotinib Viatris
• slowed growth rate in children and adolescents
• upper respiratory tract infection, including sore throat, runny nose, or stuffy nose, coughing
• low blood cell count (red blood cells, platelets) or low hemoglobin level
• high lipase activity in the blood (pancreatic function)
• high bilirubin level in the blood (liver function)
• high alanine aminotransferase activity in the blood (liver enzymes)

Some side effects are common(may affect less than 1 in 10 people)

• pneumonia
• abdominal pain, discomfort in the stomach after meals, bloating, swelling, or bloating of the abdomen
• bone pain, muscle cramps
• pain (including neck pain)
• dry skin, acne, decreased skin sensitivity
• weight loss or gain
• insomnia, depression, anxiety
• night sweats, excessive sweating
• general malaise
• nosebleeds
• gout symptoms: joint pain and swelling
• erectile dysfunction
• flu-like symptoms
• sore throat
• bronchitis
• ear pain, ringing in the ears (tinnitus), or other abnormal sounds
• petechiae
• heavy menstrual bleeding
• folliculitis
• thrush of the vagina or mouth
• conjunctivitis symptoms: discharge from the eye, accompanied by itching, redness, and swelling
• eye irritation, redness of the eyes
• hypertension symptoms: high blood pressure, headache, dizziness
• flushing
• peripheral arterial disease symptoms: pain, discomfort, weakness, or cramping of the muscles in the legs, which may be caused by reduced blood flow, ulcers on the legs or hands that heal slowly or not at all, and noticeable changes in skin color (blue or pale) or temperature (cooling) of the legs or hands (these symptoms may indicate arterial occlusion in the affected limb)
• shortness of breath
• mouth ulcers with gum inflammation (also known as stomatitis)
• high amylase activity in the blood (pancreatic function)
• high creatinine level in the blood (kidney function)
• high alkaline phosphatase or creatine kinase activity in the blood
• high aspartate aminotransferase activity in the blood (liver enzymes)
• high gamma-glutamyltransferase activity in the blood (liver enzymes)
• leukopenia or neutropenia symptoms: low white blood cell count
• high platelet or white blood cell count in the blood
• low magnesium, potassium, sodium, calcium, or phosphorus level in the blood
• high lipid level in the blood (including cholesterol)
• high uric acid level in the blood

Some side effects are uncommon(may affect less than 1 in 100 people)

• allergy (hypersensitivity to Nilotinib Viatris)
• dry mouth
• chest pain
• pain or discomfort in the side
• increased appetite
• breast enlargement in men
• herpes virus infection
• stiffness and swelling of the joints
• feeling of temperature changes (including feeling hot or cold)
• taste disturbances
• frequent urination
• gastritis symptoms: abdominal pain, nausea, vomiting, diarrhea, bloating of the abdomen
• memory loss
• skin cyst, thinning, or thickening of the skin, skin discoloration
• psoriasis symptoms: thickened, red, silvery patches of skin
• increased sensitivity of the skin to light
• hearing impairment
• arthritis
• urinary incontinence
• enteritis (also known as small intestine and colon inflammation)
• anal abscess
• nipple swelling
• restless legs syndrome symptoms: uncontrollable need to move a part of the body, usually the legs, which is accompanied by unpleasant sensations
• sepsis symptoms: fever, chest pain, rapid heartbeat, shortness of breath, or rapid breathing
• skin infection (subcutaneous abscess)
• skin warts
• high eosinophil count (a type of white blood cell)
• lymphopenia symptoms: low white blood cell count
• high parathyroid hormone level in the blood
• high lactate dehydrogenase level in the blood (an enzyme)
• low blood sugar symptoms: nausea, sweating, weakness, dizziness, shakiness, headache
• dehydration
• abnormal lipid levels in the blood
• involuntary trembling
• difficulty concentrating
• unpleasant or abnormal sensations (also known as paresthesia)
• fatigue
• tingling or numbness in the fingers or toes (also known as peripheral neuropathy)
• facial paralysis
• red spots in the white of the eye due to blood vessel damage (also known as conjunctival hemorrhage)
• blood in the eyes (also known as ocular hemorrhage)
• eye irritation
• heart attack symptoms (also known as myocardial infarction): sudden and crushing chest pain, fatigue, irregular heartbeat
• heart murmur symptoms: fatigue, discomfort in the chest, feeling of lightheadedness, pain, palpitations
• athlete's foot
• heart failure symptoms: shortness of breath, difficulty breathing when lying down, swelling of the feet or legs
• pericarditis symptoms: chest pain (also known as pericarditis)
• high blood pressure crisis symptoms: severe headache, dizziness, nausea
• intermittent claudication symptoms: pain and weakness in the legs when walking (also known as intermittent claudication)
• arterial occlusion symptoms: high blood pressure, painful cramps in the muscles of the hips, thighs, or calves when walking or climbing stairs, numbness or weakness in the legs
• bruising (without a cause such as bruising)
• fat deposits in the arteries, which can cause their blockage (also known as atherosclerosis)
• low blood pressure symptoms (also known as hypotension): feeling of lightheadedness, dizziness, or fainting
• pulmonary edema symptoms: shortness of breath
• pleural effusion symptoms: fluid accumulation between the layers of tissue lining the lungs and the chest cavity (which can reduce the heart's ability to pump blood in severe cases), chest pain, cough, hiccups, rapid breathing
• interstitial lung disease symptoms: cough, difficulty breathing, chest pain when breathing
• pleurisy symptoms: chest pain when breathing
• hoarseness
• pulmonary hypertension symptoms: high blood pressure in the pulmonary arteries
• wheezing
• tooth sensitivity
• gingivitis symptoms (also known as gum inflammation): bleeding gums, tenderness, or swelling of the gums
• high urea level in the blood (kidney function)
• changes in blood protein levels (low globulin levels or presence of paraprotein)
• high unconjugated bilirubin level in the blood
• high troponin level in the blood

Some side effects are rare(may affect less than 1 in 1,000 people)

• redness and (or) swelling and possible peeling on the palms and soles (known as palmar-plantar erythrodysesthesia syndrome)
• mouth warts
• feeling of hardening or thickening of the breasts
• thyroiditis
• mood disorders or depression
• secondary hyperparathyroidism symptoms: bone and joint pain, frequent urination, abdominal pain, weakness, fatigue
• cerebral arterial occlusion symptoms: loss of vision affecting part or all of the field of vision in both eyes, double vision, dizziness (feeling of spinning), numbness, or tingling, loss of coordination, dizziness, or confusion
• brain edema (possible headache and (or) changes in mental status)
• optic neuritis symptoms: blurred vision, loss of vision
• heart function disorders (reduced ejection fraction): fatigue, discomfort in the chest, feeling of lightheadedness, pain, palpitations
• low insulin level in the blood (a hormone that regulates blood sugar levels)
• low C-peptide level in the blood (pancreatic function)
• sudden death

The following side effects have been reported with an unknown frequency (cannot be estimated from the available data):

• heart function disorders (ventricular disorders): shortness of breath, fatigue at rest, irregular heartbeat, discomfort in the chest, feeling of lightheadedness, pain, palpitations, excessive urination, swelling of the feet, ankles, and abdomen.

Reporting side effects

If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 4921 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of this medicine.

5. How to store Nilotinib Viatris

• The medicine should be stored out of sight and reach of children.
• Do not use this medicine after the expiry date stated on the carton and blister after EXP. The expiry date refers to the last day of the month stated.
• Nilotinib Viatris, 50 mg, hard capsules: Do not store above 30°C. Nilotinib Viatris, 150 mg, hard capsules; Nilotinib Viatris, 200 mg, hard capsules: No special storage precautions are required.
• Do not use this medicine if the packaging is damaged or shows signs of tampering.
• Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the pack and other information

What Nilotinib Viatris contains

• The active substance is nilotinib.
• Each hard capsule contains 50 mg of nilotinib (as hydrochloride monohydrate). The other ingredients are:

Hard capsule contents: lactose monohydrate, crospovidone type A, colloidal anhydrous silica, magnesium stearate Capsule shell: hypromellose, purified water, carrageenan, potassium chloride, erythrosine (E127), yellow iron oxide (E172), red iron oxide (E172), titanium dioxide (E171) Printing ink: shellac, propylene glycol, potassium hydroxide, black iron oxide (E172) See section 2 "Nilotinib Viatris contains lactose and sodium".

• Each hard capsule contains 150 mg of nilotinib (as hydrochloride monohydrate). The other ingredients are: Hard capsule contents: lactose monohydrate, crospovidone type A, colloidal anhydrous silica, magnesium stearate Capsule shell: hypromellose, purified water, carrageenan, potassium chloride, erythrosine (E127), yellow iron oxide (E172), red iron oxide (E172), titanium dioxide (E171) Printing ink: shellac, propylene glycol, potassium hydroxide, black iron oxide (E172) See section 2 "Nilotinib Viatris contains lactose and sodium".
• Each hard capsule contains 200 mg of nilotinib (as hydrochloride monohydrate). The other ingredients are: Hard capsule contents: lactose monohydrate, crospovidone type A, colloidal anhydrous silica, magnesium stearate Capsule shell: hypromellose, purified water, carrageenan, potassium chloride, yellow iron oxide (E172), titanium dioxide (E171) Printing ink: shellac, propylene glycol, potassium hydroxide, black iron oxide (E172) See section 2 "Nilotinib Viatris contains lactose and sodium".

How does Nilotinib Viatris look like and what does the packaging contain

Nilotinib Viatris, 50 mg is in the form of hard capsules (capsules) size 4 (approximately 14.4 mm in length) with a light yellow opaque body and a red opaque cap, with black printing "50 mg" placed transversely on the body. The hard capsules are filled with a white to yellowish powder.
Nilotinib Viatris, 150 mg is in the form of red opaque hard capsules (capsules) size 1 (approximately 19.3 mm in length), with black printing "150 mg" placed transversely on the body. The hard capsules are filled with a white to yellowish powder.
Nilotinib Viatris, 200 mg is in the form of light yellow opaque hard capsules (capsules) size 0 (approximately 21.4 mm in length), with black printing "200 mg" placed transversely on the body. The hard capsules are filled with a white to yellowish powder.
Nilotinib Viatris, 50 mg, hard capsules are packaged:
In blisters of PVC/PE/PVdC/Aluminum or OPA/Aluminum/PVC/Aluminum foil in:
A single pack containing 112 or 120 hard capsules or a collective pack containing 112 (4 boxes of 28 pieces) or 120 (3 boxes of 40 pieces) hard capsules.
In single-dose perforated blisters of PVC/PE/PVdC/Aluminum or OPA/Aluminum/PVC/Aluminum foil in:
A single pack containing 112 x 1 or 120 x 1 hard capsules or a collective pack containing 112 x 1 (4 boxes of 28 x 1 pieces) or 120 x 1 (3 boxes of 40 x 1 pieces) hard capsules.
Nilotinib Viatris, 150 mg, hard capsules are packaged:
In blisters of PVC/PE/PVdC/Aluminum or OPA/Aluminum/PVC/Aluminum foil in:
A single pack containing 28, 112 or 120 hard capsules or a collective pack containing 112 (4 boxes of 28 pieces) or 392 (14 boxes of 28 pieces) hard capsules.
In single-dose perforated blisters of PVC/PE/PVdC/Aluminum or OPA/Aluminum/PVC/Aluminum foil in:
A single pack containing 112 x 1 or 120 x 1 hard capsules or a collective pack containing 112 x 1 (4 boxes of 28 x 1 pieces) or 392 x 1 (14 boxes of 28 x 1 pieces) hard capsules.
Nilotinib Viatris 200 mg hard capsules are packaged:
In blisters of PVC/PE/PVdC/Aluminum or OPA/Aluminum/PVC/Aluminum foil in:
A single pack containing 28, 112 or 120 hard capsules or a collective pack containing 112 (4 boxes of 28 pieces), 120 (3 boxes of 40 pieces) or 392 (14 boxes of 28 pieces) hard capsules.
In single-dose perforated blisters of PVC/PE/PVdC/Aluminum or OPA/Aluminum/PVC/Aluminum foil in:
A single pack containing 112 x 1 or 120 x 1 hard capsules or a collective pack containing 112 x 1 (4 boxes of 28 x 1 pieces) or 392 x 1 (14 boxes of 28 x 1 pieces) hard capsules.
Not all pack sizes may be marketed.

Responsible entity

Viatris Limited
Damastown Industrial Park
Mulhuddart
Dublin 15
DUBLIN
Ireland

Manufacturer

PharOS MT Limited
HF62X, Hal Far Industrial Estate
Birzebbugia, BBG 3000
Malta
To obtain more detailed information about this medicinal product, please contact the local representative of the responsible entity:
Viatris Healthcare Sp. z o.o.
Tel: +48 22 54 66 400

This medicinal product is authorized in the Member States of the European Economic Area under the following names:

Countries:

Date of last update of the leaflet:11.2024